Ulrike S. Diesterbeck, PhD is a veterinarian and life sciences executive driving innovation in animal health, with extensive experience in vaccine and biologics development from discovery through regulatory approval. As Managing Director and Chief Scientific Officer at Verovaccines GmbH, she leads the advancement of novel vaccine technologies, translating cutting-edge science into scalable, commercially viable solutions.

With a strong foundation in veterinary medicine and biomedical research, Dr. Diesterbeck has played a central role in translating cutting-edge science into market-ready solutions, including coordinating regulatory pathways for novel vaccine candidates approaching EMA review.

She has successfully guided platforms derived vaccine development through regulatory approval with the European Medicines Agency, contributing to full platform validation and enabling portfolio expansion. Her scientific background in immunology, recombinant antibodies, and protein engineering underpins a strong focus on translational innovation.

Dr. Diesterbeck combines veterinary expertise with strategic leadership to bridge science, regulation, and business. She is particularly committed to fostering innovation through cross-disciplinary collaboration and to advancing next-generation solutions that address emerging challenges in animal health.